TIE2 agonistic antibody
TIE2 agonistic antibody has been studied in 1 paper since 2017: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 18, 2017: “Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma”.
1 paper studies it2 findingsUpdated
See all 1 papers on TIE2 agonistic antibody
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Animals1
What did studies of TIE2 agonistic antibody find?
2Studies of TIE2 agonistic antibody measured 2 outcomes: Schlemm's canal integrity and primary open-angle glaucoma.
Schlemm's canal integrity
upin mice1
1 study
Schlemm's canal integrity
upin mice1
TIE2 agonistic antibody improves Schlemm's canal integrity in mice (aged mice).
“Tie2 reactivation using a Tie2 agonistic antibody rescued the POAG phenotype in Angpt1/Angpt2-deficient mice and rejuvenated the SC in aged mice”
Animalsaged miceSchlemm's canal
Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma
The Journal of clinical investigation
Primary open-angle glaucoma
downin mice1
1 study
Primary open-angle glaucoma
downin mice1
TIE2 agonistic antibody protects against primary open-angle glaucoma in mice (Angpt1/Angpt2-deficient mice).
“Tie2 reactivation using a Tie2 agonistic antibody rescued the POAG phenotype in Angpt1/Angpt2-deficient mice and rejuvenated the SC in aged mice”
AnimalsAngpt1/Angpt2-deficient mice
Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma
The Journal of clinical investigation